+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sepsis Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 291 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1882061

Quick Summary:

In the rapidly evolving landscape of the global healthcare sector, the Sepsis Therapeutics market is garnering increasing attention, reaching unprecedented heights. As estimated, it is projected to scale up from US$4.2 Billion in 2022 to an impressive US$7.1 Billion by 2030. Notable growth is observed in key segments such as Cephalosporin and Glycopeptide Antibiotics, signaling promising opportunities for prospective investors and businesses.

Emerging markets including China, Japan, Canada, and Germany are demonstrating significant expansion rates, emphasizing the globe-spanning relevance of this dynamic market. Our market research report not only provides an in-depth analysis of current trends and future trajectories, but also includes a comprehensive study of a wide range of competitors, enabling a holistic understanding of the competitive landscape. Enhanced with special features such as online interactive peer-to-peer collaborative updates and access to digital archives, this report is a valuable asset for those looking to navigate the complexities of the Sepsis Therapeutics market.

Global Sepsis Therapeutics Market to Reach $7.1 Billion by 2030

The global market for Sepsis Therapeutics estimated at US$4.2 Billion in the year 2022, is projected to reach a revised size of US$7.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2022-2030. Cephalosporin, one of the segments analyzed in the report, is projected to record 7% CAGR and reach US$3 Billion by the end of the analysis period. Growth in the Glycopeptide Antibiotics segment is estimated at 6.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 8.6% CAGR

The Sepsis Therapeutics market in the U.S. is estimated at US$1.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$776.3 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Select Competitors (Total 45 Featured)

  • Adrenomed AG
  • AM-Pharma B.V.
  • Asahi Kasei Pharma America
  • Endacea, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GSK Plc
  • InflaRx N.V.
  • Inotrem SA
  • La Jolla Pharmaceutical Company
  • TaiRx, Inc.

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Sepsis Therapeutics Market

What is the estimated value of the Sepsis Therapeutics Market?

The Sepsis Therapeutics Market was estimated to be valued at $4.2 Billion in 2022.

What is the growth rate of the Sepsis Therapeutics Market?

The growth rate of the Sepsis Therapeutics Market is 6.8%, with an estimated value of $7.1 Billion by 2030.

What is the forecasted size of the Sepsis Therapeutics Market?

The Sepsis Therapeutics Market is estimated to be worth $7.1 Billion by 2030.

Who are the key companies in the Sepsis Therapeutics Market?

Key companies in the Sepsis Therapeutics Market include Adrenomed AG, AM, Pharma B.V., Asahi Kasei Pharma America, Endacea, Inc., F. Hoffmann, La Roche Ltd., GSK Plc, InflaRx N.V. and Inotrem SA.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Sepsis: A Life-Threatening Condition Requiring Urgent Action
  • Interventions for Managing Sepsis
  • Treatments that are Commonly Applied for Sepsis
  • Impact of Covid-19 and Global Economic Update
  • From Pandemic to War & Inflation: “Gloomy Outlook for 2023 Despite Signs of Easing Inflationary Conditions”
  • Here’s How Inflationary Pressures Affect the Economy
  • Russia-Ukraine War, the Primary Culprit Responsible for the Hardships
  • Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue
  • Here’s What’s Causing Inflationary Pressures in the Global Market
  • Shaken by the War, Global Oil Prices Spiral and Feed Inflationary Pressures, Guiding the World Towards a Cost of Living Crisis: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024
  • War-Induced Commodity Price Increases & Broad Based Price Pressures Mark the Return of Global Inflation to the Highest Level Seen Since 1996: Global Inflation Rates (In %) for the Years 2019 Through 2024
  • Although Facing a Lower Recession Risk, Global Economic Growth in 2023 to Slowdown Amid War, Inflation, Elevated Interest Rates & Marginal Easing of Inflation: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
  • Recession Triggered by Uncontrolled Inflation or Unemployment, Which is the Greater Evil? Inflation Battling Policy Measures to Slowdown Post Pandemic Recovery in Unemployment Rates: Global Number of Unemployed People (In Million) for Years 2019 Through 2024
  • COVID-19 Impact on Sepsis Therapeutics
  • Competitive Landscape
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • Global Market Prospects and Outlook
  • Thriving Global Sepsis Therapeutics Market Oozes Signs of Robust Health
  • Cephalosporins Hold a Major Share of the Treatment Market
  • Global Sepsis Therapeutics Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth
  • Limited Therapeutic Options: A Challenge
  • Antibiotics and Vasopressors - The Current Standard of Care
  • Current Categories of Antibacterial Agents for First-line Sepsis Treatment
  • Current Anti-bacterial Drugs used in Sepsis
  • Current Antifungals used for Sepsis
  • GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
  • Promising Treatment for Sepsis
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Sepsis Propels Market Growth
  • Aging Population: A Key Growth Driver for Sepsis Therapeutics
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • A Market Characterized by High Unmet Medical Needs
  • Novel Immune-Specific Modes of Action under Focus
  • Emphasizing on Endothelial Cell Function
  • HMGB1- A Potential Target for Future Therapies
  • Hydrocortisone Displays Potential in Septic Shock Treatment
  • Reduced Levels of Vitamin C Characterize Sepsis Patients
  • Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
  • Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
  • Anticancer Drugs - Offering Potential Treatment of Sepsis
  • New Protein to be Effective for Sepsis
  • Rise in Healthcare Expenditure to Drive Growth
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • AI-Driven Sepsis Screening Approach to Save Lives
  • Increasing R&D Activity & New Product Launches Spur Market Growth
  • Purdue Researchers Develop IV Injection for Sepsis
  • PLK1-mTOR Axis - A Potential Therapeutic for Sepsis
  • New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy
  • Strong Pipeline and Increased Research Activity Enables Increased Awareness of Disease Pathogenesis
  • Select Sepsis Therapeutics & Treatments under Phase IV Clinical Trials: As of 2022
  • Select Sepsis Therapeutics & Treatments under Phase III Clinical Trials: As of 2022
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Sepsis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 4: World 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 7: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 10: World 16-Year Perspective for Glycopeptide Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 13: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 19: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • CANADA
  • JAPAN
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • CHINA
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • EUROPE
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • FRANCE
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • GERMANY
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • ITALY
  • UNITED KINGDOM
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • AUSTRALIA
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • MIDDLE EAST
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • AFRICA
  • Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Adrenomed AG
  • AM-Pharma B.V.
  • Asahi Kasei Pharma America
  • Endacea, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GSK Plc
  • InflaRx N.V.
  • Inotrem SA
  • La Jolla Pharmaceutical Company
  • TaiRx, Inc.